

International AIDS Conference 2026, Rio de Janeiro, Brazil:
Satellite | Monday, July 27, 2026, 9:30 – 11:00 | 103

Advances in HIV post-exposure prophylaxis (PEP): Regulatory challenges and clinical trial designs

The symposium will comprise a mix of presentations and panel discussions with audience participation. A satellite description is listed below the draft agenda.

Session Topic Presentation Information	Duration	Facilitators/Speakers & Notes
Introduction – background & framing of session, objectives, outcomes and Wits RHI Perspective	10min	Speakers: - Veronica Miller, Forum for Collaborative Research - Sinead Delany-Moretlwe, Wits RHI
Key findings from the HIV PEP Summit Highlights of the discussion surrounding PEP implementation and trial design	15min	Speaker: Andrew Mujugira, Infectious Diseases Institute
Funder perspectives	10min	Speaker: Max Latiallade, Gates Foundation
Community perspectives	10min	Speaker: Adaobi Olisa, Root to Rise
Moderated Discussion: (15min + 30 min Q&A) <i>Moderated audience questions</i>	40min	Moderators: - Ken Mayer, The Fenway Institute - Veronica Miller, Forum for Collaborative Research Panel Members: - All Speakers + - Adriano Queiroz da Silva, STI/AIDS Coordination Office, City of São Paulo - Kenneth Ngunjiri, Jomo Kenyatta University (JKUAT) & University of Washington - Boitumelo Semete, South African Health Products Regulatory Authority
Summary/closure	5 min	Speaker: Veronica Miller, Forum for Collaborative Research

Satellite Description: Advances in HIV post-exposure prophylaxis (PEP): Regulatory challenges and clinical trial designs

This symposium highlights deliberations on the future of HIV post exposure prophylaxis (PEP) clinical trial designs, data collection, and regulatory challenges by a working group via the Forum for Collaborative Research at the University of California, Berkeley. This working group brings together diverse stakeholders from different regions to discuss pressing issues relating to the future of HIV PEP. Through a series of presentations and discussions, the symposium aims to highlight and extend the discussion of challenges to and potential solutions for inclusive HIV PEP research that began during the HIV PEP Summit on May 11 and 12 in Johannesburg South Africa. Designing HIV PEP clinical trials requires coordinated efforts and consensus building among researchers, funders, regulatory agencies, community organizations, and policymakers. By emphasizing the importance of collaboration, the symposium deliberates possible pathways on the future of ethical, efficient, and feasible HIV PEP efficacy evaluation, and levels of evidence to inform HIV PEP Guidelines and possible regulatory approval.